RC 48Alternative Names: RC 48-ADC; RC-48
Latest Information Update: 02 Sep 2016
At a glance
- Originator Yantai Rongchang Biological Engineering
- Class Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Nov 2015 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (SC) (NCT02881138)